July 22, 2016 / 7:47 AM / in a year

FDA raises concerns over Valeant's eye drop

(Reuters) - Valeant Pharmaceuticals International (VRX.TO) (VRX.N) said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.

A sign for the headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec June 14, 2016. REUTERS/Christinne Muschi

The U.S. Food and Drug Administration, in a complete response letter (CRL) regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit.

The letter did not identify any efficacy or safety issues with the eye drop, a latanoprostene bunod ophthalmic solution.

Valeant said it intends to meet the regulators and resolve these concerns, the company said in a statement.

Eye care unit Bausch + Lomb is one of Valeant’s core assets and a franchise to build on, billionaire investor and Valeant board member Bill Ackman said last week.

Reporting by Ismail Shakil in Bengaluru; Editing by Sunil Nair

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below